Drug project high-priority medications
WikiDoc Drug Project — High-Priority Medications
- Template here: Drug page template
- Example here: Clopidogrel
- FDA package insert here: DailyMed
List of high-priority medications
Novel Drug Approvals for 2021
No. | Drug Name | Active Ingredient | Approval Date | FDA-approved use on approval date |
---|---|---|---|---|
42 | Scemblix | asciminib | 10/29/2021 | To treat Philadelphia chromosome-positive chronic myeloid leukemia with disease that meets certain criteria |
41 | Tavneos | avacopan | 10/7/2021 | To treat severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy, including glucocorticoids |
40 | Livmarli | maralixibat | 9/29/2021 | To treat cholestatic pruritus associated with Alagille syndrome |
39 | Qulipta | atogepant | 9/28/2021 | To prevent episodic migraines |
38 | Tivdak | tisotumab vedotin-tftv | 9/20/2021 | To treat recurrent or metastatic cervical cancer with disease progression on or after chemotherapy |
37 | Exkivity | mobocertinib | 9/15/2021 | To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations |
36 | Skytrofa | lonapegsomatropin-tcgd | 8/25/2021 | To treat short stature due to inadequate secretion of endogenous growth hormone |
35 | Korsuva | difelikefalin | 8/23/2021 | To treat moderate-to-severe pruritus associated with chronic kidney disease in certain populations |
34 | Welireg | belzutifan | 8/13/2021 | To treat von Hippel-Lindau disease under certain conditions |
33 | Nexviazyme | avalglucosidase alfa-ngpt | 8/6/2021 | To treat late-onset Pompe disease |
32 | Saphnelo | anifrolumab-fnia | 7/30/2021 | To treat moderate-to severe systemic lupus erythematousus along with standard therapy |
31 | Bylvay | odevixibat | 7/20/2021 | To treat pruritus |
30 | Rezurock | belumosudil | 7/16/2021 | To treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy |
29 | fexinidazole | fexinidazole | 7/16/2021 | To treat human African trypanosomiasis caused by the parasite Trypanosoma brucei gambiense |
28 | Kerendia | finerenone | 7/9/2021 | To reduce the risk of kidney and heart complications in chronic kidney disease associated with type 2 diabetes |
27 | Rylaze | asparaginase erwinia chrysanthemi (recombinant)-rywn | 6/30/2021 | To treat acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who are allergic to E. coli-derived asparaginase products, as a component of a chemotherapy regimen |
26 | Aduhelm | aducanumab-avwa | 6/7/2021 | To treat Alzheimer’s disease |
25 | Brexafemme | ibrexafungerp | 6/1/2021 | To treat vulvovaginal candidiasis |
24 | Lybalvi | olanzapine and samidorphan | 5/28/2021 | To treat schizophrenia and certain aspects of bipolar I disorder |
23 | Truseltiq | infigratinib | 5/28/2021 | To treat cholangiocarcinoma whose disease meets certain criteria |
22 | Lumakras | sotorasib | 5/28/2021 | To treat types of non-small cell lung cancer |
21 | Pylarify | piflufolastat F 18 | 5/26/2021 | To identify prostate-specific membrane antigen-positive lesions in prostate cancer |
20 | Rybrevant | amivantamab-vmjw | 5/21/2021 | To treat a subset of non-small cell lung cancer |
19 | Empaveli | pegcetacoplan | 5/14/2021 | To treat paroxysmal nocturnal hemoglobinuria |
18 | Zynlonta | loncastuximab tesirine-lpyl | 4/23/2021 | To treat certain types of relapsed or refractory large B-cell lymphoma |
17 | Jemperli | dostarlimab-gxly | 4/22/2021 | To treat endometrial cancer |
16 | Nextstellis | drospirenone and estetrol | 4/15/2021 | To prevent pregnancy |
15 | Qelbree | viloxazine | 4/2/2021 | To treat attention deficit hyperactivity disorder |
14 | Zegalogue | dasiglucagon | 3/22/2021 | To treat severe hypoglycemia |
13 | Ponvory | ponesimod | 3/18/2021 | To treat relapsing forms of multiple sclerosis |
12 | Fotivda | tivozanib | 3/10/2021 | To treat renal cell carcinoma |
11 | Azstarys | "serdexmethylphenidate and | ||
dexmethylphenidate" | 3/2/2021 | To treat attention deficit hyperactivity disorder | ||
10 | Pepaxto | melphalan flufenamide | 2/26/2021 | To treat relapsed or refractory multiple myeloma |
9 | Nulibry | fosdenopterin | 2/26/2021 | To reduce the risk of mortality in molybdenum cofactor deficiency Type A |
8 | Amondys 45 | casimersen | 2/25/2021 | To treat Duchenne muscular dystrophy |
7 | Cosela | trilacicilib | 2/12/2021 | To mitigate chemotherapy-induced myelosuppression in small cell lung cancer |
6 | Evkeeza | evinacumab-dgnb | 2/11/2021 | To treat homozygous familial hypercholesterolemia |
5 | Ukoniq | umbralisib | 2/5/2021 | To treat marginal zone lymphoma and follicular lymphoma |
4 | Tepmetko | tepotinib | 2/3/2021 | To treat non-small cell lung cancer |
3 | Lupkynis | voclosporin | 1/22/2021 | To treat lupus nephritis |
2 | Cabenuva | cabotegravir and rilpivirine (co-packaged) | 1/21/2021 | To treat HIV |
1 | Verquvo | vericiguat | 1/19/2021 | To mitigate the risk of cardiovascular death and hospitalization for chronic heart failure |
Novel Drug Approvals for 2020
No. | Drug Name | Active Ingredient | Approval Date | FDA-approved use on approval date |
---|---|---|---|---|
53 | Gemtesa | vibegron | 12/23/2020 | To treat overactive bladder |
52 | Ebanga | ansuvimab-zykl | 12/21/2020 | To treat ebola |
51 | Orgovyx | relugolix | 12/18/2020 | To treat advanced prostate cancer |
50 | Margenza | margetuximab (anti-HER2 mAb | 12/16/2020 | To treat HER2+ breast cancer |
49 | Klisyri | tirbanibulin | 12/14/2020 | To treat actinic Keratosis of the face or scalp |
48 | Orladeyo | berotralstat | 12/3/2020 | To treat patients with hereditary angioedema |
47 | Gallium 68 PSMA-11 | Gallium 68 PSMA-11 | 12/1/2020 | For detection and localization of prostate cancer |
46 | Danyelza | naxitamab-gqgk | 11/25/2020 | To treat high-risk refractory or relapsed neuroblastoma |
45 | Imcivree | setmelanotide | 11/25/2020 | To treat obesity and the control of hunger associated with pro-opiomelanocortin deficiency, a rare disorder that causes severe obesity that begins at an early age |
44 | Oxlumo | lumasiran | 11/23/2020 | To treat hyperoxaluria type 1 |
43 | Zokinvy | lonafarnib | 11/20/2020 | To treat rare conditions related to premature aging |
42 | Veklury | remdesivir | 10/22/2020 | To treat COVID-19 |
41 | Inmazeb | atoltivimab, maftivimab, and odesivimab-ebgn | 10/14/2020 | To treat ebola virus |
40 | Gavreto | pralsetinib | 9/4/2020 | To treat non-small lung cancer |
39 | Detectnet | copper Cu 64 dotatate injection | 9/3/2020 | To help detect certain types of neuroendocrine tumors |
38 | Sogroya | somapacitan-beco | 8/28/2020 | Growth hormone |
37 | Winlevi | clascoterone | 8/26/2020 | To treat acne |
36 | Enspryng | satralizumab-mwge | 8/14/2020 | To treat neuromyelitis optica spectrum disorder |
35 | Viltepso | viltolarsen | 8/12/2020 | To treat Duchenne muscular dystrophy |
34 | Olinvyk | oliceridine | 8/7/2020 | To manage acute pain in certain adults |
33 | Evrysdi | risdiplam | 8/7/2020 | To treat spinal muscular atrophy |
32 | Lampit | nifurtimox | 8/6/2020 | To treat Chagas disease in certain pediatric patients younger than age 18 |
31 | Blenrep | belantamab mafodotin-blmf | 8/5/2020 | To treat multiple myeloma |
30 | Monjuvi | tafasitamab-cxix | 7/31/2020 | To treat relapsed or refractory diffuse large B-cell lymphoma |
29 | Xeglyze | abametapir | 7/24/2020 | To treat head lice |
28 | Inqovi | decitabine and cedazuridine | 7/7/2020 | To treat adult patients with myelodysplastic syndromes |
27 | Rukobia | fostemsavir | 7/2/2020 | To treat HIV |
26 | Byfavo | remimazolam | 7/2/2020 | For sedation |
25 | Dojolvi | triheptanoin | 6/30/2020 | To treat molecularly long-chain fatty acid oxidation disorders |
24 | Zepzelca | lurbinectedin | 6/15/2020 | To treat metastatic small cell lung cancer |
23 | Uplizna | inebilizumab-cdon | 6/11/2020 | To treat neuromyelitis optica spectrum disorder |
22 | Tauvid | flortaucipir F18 | 5/28/2020 | Diagnostic agent for patients with Alzheimer’s disease |
21 | Artesunate | artesunate | 5/26/2020 | To treat severe malaria |
20 | Cerianna | fluoroestradiol F18 | 5/20/2020 | Diagnostic imaging agent for certain patients with breast cancer |
19 | Qinlock | ripretinib | 5/15/2020 | To treat advanced gastrointestinal-stromal tumors |
18 | Retevmo | selpercatinib | 5/8/2020 | To treat lung and thyroid cancers |
17 | Tabrecta | capmatinib | 5/6/2020 | To treat patients with non small cell lung cancer |
16 | Ongentys | opicapone | 4/24/2020 | To treat patients with Parkinson’s disease experiencing “off” episodes |
15 | Trodelvy | sacituzumab govitecan-hziy | 4/22/2020 | To treat adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease |
14 | Pemazyre | pemigatinib | 4/17/2020 | To treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts |
13 | Tukysa | tucatinib | 4/17/2020 | To treat advanced unresectable or metastatic HER2-positive breast cancer |
12 | Koselugo | selumetinib | 4/10/2020 | To treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves |
11 | Zeposia | ozanimod | 3/25/2020 | To treat relapsing forms of multiple sclerosis |
10 | Isturisa | osilodrostat | 3/6/2020 | To treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease |
9 | Sarclisa | isatuximab | 3/2/2020 | To treat multiple myloma |
8 | Nurtec ODT | rimegepant | 2/27/2020 | To treat migraine |
7 | Barhemsys | amisulpride | 2/26/2020 | To help prevent nausea and vomiting after surgery |
6 | Vyepti | eptinezumab-jjmr | 2/21/2020 | For the preventive treatment of migraine in adults |
5 | Nexletol | bempedoic acid | 2/21/2020 | To treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C |
4 | Pizensy | lactitol | 2/12/2020 | To treat chronic idiopathic constipation (CIC) in adults |
3 | Tazverik | tazemetostat | 1/23/2020 | To treat epithelioid sarcoma |
2 | Tepezza | teprotumumab-trbw | 1/21/2020 | To treat Thyroid eye disease |
1 | Ayvakit | avapritinib | 1/9/2020 | To treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) |
Novel Drug Approvals for 2019
No. | Drug Name | Active Ingredient | Approval Date | FDA-approved use on approval date |
---|---|---|---|---|
48 | Ubrelvy | ubrogepant | 12/23/2019 | to treat acute treatment of migraine with or without aura in adults |
47 | Enhertu | fam-trastuzumab deruxtecan-nxki | 12/20/2019 | To treat metastatic breast cancer |
46 | Dayvigo | lemborexant | 12/20/2019 | To treat insomnia |
45 | Caplyta | lumateperone tosylate | 12/20/2019 | To treat schizophrenia |
44 | TissueBlue | Brilliant Blue G Ophthalmic Solution | 12/20/2019 | Dye used in eye surgery |
43 | Padcev | enfortumab vedotin-ejfv | 12/18/2019 | To treat refractory bladder cancer |
42 | Vyondys 53 | golodirsen | 12/12/2019 | To treat certain patients with Duchenne muscular dystrophy |
41 | Oxbryta | voxelotor | 11/25/2019 | To treat sickle cell disease |
40 | Xcopri | cenobamate | 11/21/2019 | To treat partial onset seizures |
39 | Givlaari | givosiran | 11/20/2019 | To treat acute hepatic porphyria, a rare blood disorder |
38 | Adakveo | crizanlizumab-tmca | 11/15/2019 | To treat patients with painful complication of sickle cell disease |
37 | Fetroja | cefiderocol | 11/14/2019 | To treat patients with complicated urinary tract infections who have limited or no alternative treatment options |
36 | Brukinsa | zanubrutinib | 11/14/2019 | To treat certain patients with mantle cell lymphoma, a form of blood cancer |
35 | Reblozyl | luspatercept–aamt | 11/8/2019 | For the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions |
34 | ExEm Foam | air polymer-type A | 11/7/2019 | A diagnostic agent used to assess fallopian tube patency (openness) in women with known or suspected infertility |
33 | Trikafta | elexacaftor/ivacaftor/tezacaftor | 10/21/2019 | To treat patients 12 years of age and older with the most common gene mutation that causes cystic fibrosis |
32 | Reyvow | lasmiditan | 10/11/2019 | For the acute treatment of migraine with or without aura, in adults |
31 | fluorodopa F 18 | 10/10/2019 | A diagnostic agent for use in positron emission tomography (PET) to help diagnose adult patients with suspected Parkinsonian syndromes (PS) | |
30 | Scenesse | afamelanotide | 10/8/2019 | To increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria |
29 | Beovu | brolucizumab–dbll | 10/7/2019 | Treatment of wet age-related macular degeneration |
28 | Aklief | trifarotene | 10/4/2019 | For the topical treatment of acne vulgaris in patients 9 years of age and older |
27 | Ibsrela | tenapanor | 9/12/2019 | To treat irritable bowel syndrome with constipation in adults. |
26 | Nourianz | istradefylline | 8/27/2019 | To treat adult patients with Parkinson’s disease experiencing “off” episodes |
25 | Ga-68-DOTATOC | Ga-68-DOTATOC | 8/21/2019 | For use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) |
24 | Xenleta | lefamulin | 8/19/2019 | To treat adults with community-acquired bacterial pneumonia |
23 | Rinvoq | upadacitinib | 8/16/2019 | To treat adults with moderately to severely active rheumatoid arthritis |
22 | Inrebic | fedratinib | 8/16/2019 | To treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis |
21 | Rozlytrek | entrectinib | 8/15/2019 | To treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive |
20 | Wakix | pitolisant | 8/14/2019 | To treat excessive daytime sleepiness (EDS) in adult patients with narcolepsy |
19 | pretomanid | 8/14/2019 | For treatment-resistant forms of tuberculosis that affects the lungs | |
18 | Turalio | pexidartinib | 8/2/2019 | To treat adult patients with symptomatic tenosynovial giant cell tumor |
17 | Nubeqa | darolutamide | 7/30/2019 | To treat adult patients with non-metastatic castration resistant prostate cancer |
16 | Accrufer | ferric maltol | 7/25/2019 | To treat iron deficiency anemia in adults |
15 | Recarbrio | imipenem, cilastatin and relebactam | 7/16/2019 | To treat complicated urinary tract and complicated intra-abdominal infections |
14 | Xpovio | selinexor | 7/3/2019 | To treat adult patients with relapsed or refractory multiple myeloma (RRMM) |
13 | Vyleesi | bremelanotide | 6/21/2018 | To treat hypoactive sexual desire disorder in premenopausal women. |
12 | Polivy | polatuzumab vedotin-piiq | 6/10/2019 | To treat adult patients with relapsed or refractory diffuse large B-cell lymphoma |
11 | Piqray | alpelisib | 5/24/2019 | To treat breast cancer |
10 | Vyndaqel | tafamidis meglumine | 5/3/2019 | To treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults |
9 | Skyrizi | risankizumab-rzaa | 4/23/2019 | To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy |
8 | Balversa | erdafitinib | 4/12/2019 | To treat adult patients with locally advanced or metastatic bladder cancer |
7 | Evenity | romosozumab-aqqg | 4/9/2019 | To treat osteoporosis in postmenopausal women at high risk of fracture |
6 | Mayzent | siponimod | 3/26/2019 | To treat adults with relapsing forms of multiple sclerosis |
5 | Sunosi | solriamfetol | 3/20/2019 | To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea |
4 | Zulresso | brexanolone | 3/19/2019 | To treat postpartum depression (PPD) in adult women |
3 | Egaten | triclabendazole | 2/13/2019 | To treat fascioliasis, a parasitic infestation caused by two species of flatworms or trematodes that mainly the affect the liver, sometimes referred to as “liver flukes” |
2 | Cablivi | caplacizumab-yhdp | 2/6/2019 | To treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP) |
1 | Jeuveau | prabotulinumtoxinA-xvfs | 2/1/2019 | For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients |